Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2019

View Archived Issues

Psychiatric risk genes can have distinct effects in different disorders

Mouse model devised to understand the potential of autophagy enhancers in treating ALS

FDA approves IND for phase I trial of TransThera's TT-00920 for heart failure

Hyper-sialylated IgG product M-254 well tolerated in healthy subjects in first-in-human trial

Topline data reported from phase II study of ARQ-151 in atopic dermatitis

Alnylam presents topline data from ILLUMINATE-A phase III study of lumasiran

Cerevance and Takeda collaborate to advance novel therapies for gastrointestinal disorders

KIN-8194 overcomes BTK C481S-mediated ibrutinib resistance in preclinical models

Peloton Therapeutics discloses new 5'-nucleotidase inhibitors

D-amino-acid oxidase inhibitors discovered at SyneuRx International

Roche patents bacterial DNA gyrase and/or DNA topoisomerase IV inhibitors

FronThera US Pharmaceuticals presents ENPP2 inhibitors

New analgesics identified at CerSci Therapeutics

Phase I results of intratumoral administration of tigilanol tiglate support further development

Pilot clinical results for ondansetron in patients with bipolar disorder and alcohol dependence

First-in-class RSK inhibitor PMD-026 shows promise for triple-negative breast cancer

New human autoinflammatory disease discovered

Adamas reports results of phase III study of ADS-5102 in MS with walking impairment

INB-03 phase I data support progression to phase II in breast cancer

Homology reports initial data from phase I/II study of HMI-102 gene therapy in PKU

DiaMedica initiates phase II study of DM-199 in chronic kidney disease

ARM-210 studied in new clinical trial for ryanodine receptor type 1-related myopathies

Phase Ib data on PXL-065 support progression to phase II for NASH

Nordic Nanovector receives funding to support Alpha37 program

BioInvent and MSD enter clinical trial collaboration to study BI-1206 with Keytruda in solid tumors

Proteostasis reports phase II topline data on CFTR modulator combinations in cystic fibrosis